{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:06:23Z","timestamp":1775570783183,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Fumarate hydratase-deficient renal cell carcinoma is a rare type of renal cell carcinoma often associated with hereditary leiomyomatosis and renal cell carcinoma syndrome. These tumors tend to exhibit an aggressive behavior and metastasize at an early stage. We describe the case of a 41-year-old woman of Chinese ethnicity who presented with progressive left flank pain and macroscopic hematuria. Computed tomography (CT) scan of the abdomen showed a large renal mass occupying the entire left kidney, left renal vein and inferior vena cava (IVC) tumor thrombus extension, left renal hilar lymphadenopathy, and indeterminate iliac bony and multiple large uterine fibroids. The patient underwent radical nephrectomy, caval thrombectomy and IVC reconstruction, total abdominal hysterectomy, and bilateral salpingo-oophorectomies. Histopathological examination revealed metastatic fumarate hydratase-deficient renal cell carcinoma associated with uterine leiomyomatosis with R1 resection margin at IVC. Owing to the lack of uniformly agreed guidelines for the management of this tumor, close surgical surveillance was advised. The patient subsequently developed postoperative liver metastases and sought self-funded medical care abroad. She subsequently received bevacizumab and erlotinib and achieved a favorable response. However, the patient experienced renal impairment with proteinuria following treatment, and the next cycle of systemic therapy was delayed. During this pause, we proceeded with stereotactic body radiation therapy (SBRT) to the remaining solitary liver metastasis. This case illustrates the practical challenges faced in treating fumarate hydratase-deficient renal cell carcinoma, including the lack of established systemic treatment guidelines and management of treatment-related adverse events. It highlights the value of integrating radiotherapy during interruptions in systemic therapy and the importance of multidisciplinary collaboration in this rare tumor.<\/jats:p>","DOI":"10.3389\/fonc.2026.1729830","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:32:47Z","timestamp":1771392767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A patient with metastatic fumarate hydratase-deficient renal cell carcinoma associated with leiomyomatosis: real-world clinical insights on systemic therapy and liver-directed SBRT"],"prefix":"10.3389","volume":"16","author":[{"given":"Huili James","family":"Chong","sequence":"first","affiliation":[{"name":"Department of Oncology, Mahkota Medical Centre","place":["Melaka, Malaysia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Canterbury Health Laboratories","place":["Christchurch, New Zealand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Jeat","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mahkota Medical Centre","place":["Melaka, Malaysia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 world health organization classification of tumors of the urinary system and male genital organs\u2014Part A: renal, penile, and testicular tumors","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.11.002","article-title":"Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals","volume":"3","author":"Forde","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40644-021-00392-9","article-title":"Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study","volume":"21","author":"Nikolovski","year":"2021","journal-title":"Cancer Imaging"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase\u2013deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase\u2013deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-021-00268-8","article-title":"A patient with very early onset FH-deficient renal cell carcinoma diagnosed at age seven","volume":"21","author":"Taniguchi","year":"2022","journal-title":"Fam Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-018-0076-4","article-title":"A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC)","volume":"17","author":"Bhola","year":"2018","journal-title":"Fam Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/jmg.2005.033506","article-title":"Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer","volume":"43","author":"Wei","year":"2006","journal-title":"J Med Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","article-title":"Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis","volume":"79","author":"Smit","year":"2011","journal-title":"Clin Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cge.13014","article-title":"Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers","volume":"92","author":"Muller","year":"2017","journal-title":"Clin Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America","volume":"73","author":"Toro","year":"2003","journal-title":"Am J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S42097","article-title":"Hereditary leiomyomatosis and renal cell carcinoma","volume":"7","author":"Schmidt","year":"2014","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2022.12.013","article-title":"Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma","volume":"134","author":"Mannan","year":"2023","journal-title":"Hum Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN guidelines\u00ae Insights: kidney cancer, version 1.2026","volume":"22","author":"Motzer","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up&x2606;","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2025.43.5_suppl.443","article-title":"Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study","volume":"43","author":"Kong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2497","article-title":"Sintilimab plus axitinib for advanced fumarate hydratase\u2013deficient renal cell carcinoma: A phase 2 nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e240073","DOI":"10.1530\/EDM-24-0073","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC), pheochromocytoma (PCC)\/paraganglioma (PGL) and germline fumarate hydratase (FH) variants","volume":"2024","author":"Orrego","year":"2024","journal-title":"Endocrinology Diabetes Metab Case Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.21037\/acr-25-40","article-title":"Fumarate hydratase-deficient renal cell carcinoma with sarcomatoid features: a case report","volume":"9","author":"Wang","year":"2025","journal-title":"AME Case Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e390038","DOI":"10.1200\/EDBK_390038","article-title":"State of the art: multidisciplinary management of oligometastatic renal cell carcinoma","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1729830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:32:48Z","timestamp":1771392768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1729830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1729830"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1729830","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1729830"}}